Camden Capital, LLC Cytokinetics Inc Transaction History
Camden Capital, LLC
- $887 Million
- Q4 2024
A detailed history of Camden Capital, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Camden Capital, LLC holds 5,204 shares of CYTK stock, worth $230,849. This represents 0.03% of its overall portfolio holdings.
Number of Shares
5,204
Previous 5,056
2.93%
Holding current value
$230,849
Previous $266,000
8.27%
% of portfolio
0.03%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding CYTK
# of Institutions
397Shares Held
122MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$651 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$529 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$477 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.89MShares$350 Million0.07% of portfolio
-
State Street Corp Boston, MA6.17MShares$274 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.18B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...